Reversibility

Tynt Technologies Closes 2023 with Successful Seed Round, Partnerships, and Growth

Retrieved on: 
Thursday, January 25, 2024
Stanford University, Helio (wireless carrier), Privacy, Traction, CFO, Reversibility, Business development, Growth, KOMPAS, Built environment, Flex, RME, Cassette tape

BOULDER, Colo., Jan. 25, 2024 /PRNewswire-PRWeb/ -- Tynt Technologies, Inc., the developer of the first-ever blackout dynamic ultra-energy-efficient window, enters 2024 on the heels of a year full of significant growth underscored by a successful seed round, world-class partnerships, breakthrough technology developments, and leadership additions.

Key Points: 
  • In 2023, Tynt closed a $7.1 million Seed II led by KOMPAS.
  • Showcased at the NREL Industry Growth Forum, this was the first time a full blackout dynamic window has been shown.
  • "Last year was a serious turning point for Tynt Technologies," said Ameen K. Saafir , CEO and co-founder of Tynt.
  • "This is an incredibly exciting time to join Tynt Technologies," said Crystal Petersen, VP of Business Development.

Florida Cancer Specialists & Research Institute Contributing to Cutting-Edge Advancements in Hematology Science

Retrieved on: 
Wednesday, December 13, 2023
Annual Reviews (publisher), ASH, BTK, Research, Bortezomib, Omicron, Conference, Bangladesh Technical Education Board, Poster, Mantle cell lymphoma, SLL, Risk, Science, Abstract, Drug development, Tyrosine kinase, Society, B-cell lymphoma, FACP, Rituximab, Reversibility, Delta, Phase, Nivolumab, Hospital, Safety, DRD, MCL, FCS, FDA, Lymphocytosis, Pivotal trial, Chronic lymphocytic leukemia, Meta-analysis, Artery, Bias, Coronary thrombosis, NHL, CLL, Pharmaceutical industry, Dietary supplement, Vaccine, Birth control, Incidence, Patient, Dexamethasone, Lenalidomide, Hematology, Relapse, Dacarbazine, MD, Doxorubicin

FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023. Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.

Key Points: 
  • FORT MYERS, Fla., Dec. 13, 2023 /PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition in San Diego on Dec. 9 - 12, 2023.
  • Scientific abstracts submitted by FCS hematologists and medical oncologists were among the 7,000 accepted submissions selected through an extensive peer review process.
  • Pirtobrutinib has also been approved for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
  • Once again, FCS is proud to have a strong presence, sharing the latest and most promising research and science that is moving the field forward."

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Eli Lilly and Company, Experiment, NYSE, Reversibility, Prior, SLL, Use, LLY, Safety, Chronic lymphocytic leukemia, Mantle cell lymphoma, Covalent bond, Medication discontinuation, Society, ASH, Lymphocytosis, Tyrosine kinase, CLL, Poster, MCL, Lymphoid leukemia, Therapy, BTK, Manchester Grand Hyatt Hotel, Pharmaceutical industry, Vaccine, Hotel, Patient

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.

Key Points: 
  • INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
  • The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.
  • In mantle cell lymphoma (MCL), an oral presentation will provide updated safety and efficacy results of pirtobrutinib in all patients, including those with biologically high-risk relapsed or refractory MCL.
  • Additionally, poster presentations will provide data on the clinical impact of pirtobrutinib following cBTKi treatment across other B-cell malignancies.

FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma

Retrieved on: 
Tuesday, February 14, 2023
AOCNP, MCL, NHL, Estate (law), Spleen, Drug development, National Institute of Nursing Research, FCS, Abstract, B-cell lymphoma, Reversibility, Diagnosis, Safety, Bone marrow, Hematology, Patient, Clinician Administered PTSD Scale, Liver, Lymph, Mantle cell lymphoma, Relapse, FACP, Clinical research, FDA, Growth, Prognosis, MSN, Progression-free survival, Society, BTK, Cancer, MD, Pharmaceutical industry, Vaccine

"It is rewarding to see the impact of our work in developing this drug from the initial trial."

Key Points: 
  • "It is rewarding to see the impact of our work in developing this drug from the initial trial."
  • - Manish Patel, MD
    Pirtobrutinib (Jaypirca™) is the first next-generation BTK inhibitor specifically approved by the FDA for adult patients with mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL), which affects about one in 200,000 people worldwide each year.
  • Following an expedited review of the outcomes observed in the BRUIN 18001 study, the FDA granted Pirtobrutinib an accelerated approval.
  • To read the full study abstract: https://ash.confex.com/ash/2022/webprogram/Paper157058.html
    Access the current list of FCS clinical trials: https://flcancer.com/clinical-trials/

Florida Cancer Specialists & Research Institute Research Breakthroughs Presented at Global Hematology Gathering

Retrieved on: 
Tuesday, December 13, 2022
Chronic lymphocytic leukemia, Role, ASH, AML, American Society of Clinical Oncology, Research, COVID-19, Menin, Hematology, Stanford University, Acute leukemia, Diagnosis, FACP, Prednisone, Health, University of Florida Cancer and Genetics Research Complex, Reversibility, Rituximab, Meta-analysis, Doctor of Pharmacy, Daratumumab, Society, Duke, Tyrosine kinase, ASCO, Hope, News, Quality of life, FCS, BTK, Safety, U.S. News & World Report, Immunotherapy, Drug development, Phase, Physician, Poster, Memorial Sloan Kettering Cancer Center, Covalent bond, Monroe Dunaway Anderson, Harvard University, Pharmaceutical industry, MD, Relapse, Vincristine, Acalabrutinib, Cyclophosphamide, Patient, Doxorubicin, Venous thrombosis

Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the diagnosis and treatment of blood diseases was presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition in New Orleans, Louisiana on Dec. 10 – 13, 2022.

Key Points: 
  • Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the diagnosis and treatment of blood diseases was presented at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition in New Orleans, Louisiana on Dec. 10 – 13, 2022.
  • “The abstracts being presented with FCS participation represent important, novel research and are considered among the best in the field of hematology,” said FCS President & Managing Physician Michael Diaz, MD .
  • Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

Ecommerce Pioneer and Overstock.com Veteran Stormy Simon Launches Mother Ruggers, the First Washable Luxury Rug Company

Retrieved on: 
Thursday, November 24, 2022
Overstock.com, High Point Market, Reversibility, Trust (social science), Entrepreneurship, Knowledge, Overstock, World Market Center Las Vegas, Textile, Collection, Black Friday, Showplace, Yıldırım, Carpet, Rugger

LAS VEGAS, Nov. 23, 2022 /PRNewswire/ -- Stormy Simon, corporate renegade and past President of Overstock.com , has partnered with Turkish manufacturer and designer Ayse Yildirim to introduce Mother Ruggers, the first washable luxury rug company.

Key Points: 
  • LAS VEGAS, Nov. 23, 2022 /PRNewswire/ -- Stormy Simon, corporate renegade and past President of Overstock.com , has partnered with Turkish manufacturer and designer Ayse Yildirim to introduce Mother Ruggers, the first washable luxury rug company.
  • Founded in late 2021, Mother Ruggers are uniquely woven rug collections with innovative engineering to create machine-washable area rugs.
  • What makes our company special is that there is no middleman - we control the process from thread to doorstep.
  • Orlena LLC., the wholesale mother company of Mother Ruggers, distributes rugs, pillows, and textiles exclusively from their boutique manufacturing facility in Turkey.

Latest Bedding Lists New Sheet and Comforter Offerings in Time for Holiday Season

Retrieved on: 
Saturday, November 27, 2021
Sale, Marketing, Gold, Charcoal, Black Friday, Nile, Collection, The Hotel Collection, Reversibility, Linens, Carpet, Interior design

"At Latest Bedding, we're passionate about giving families access to beautiful bedding at prices that won't break the bank," said Ali Hassan, Director of Marketing at Latest Bedding.

Key Points: 
  • "At Latest Bedding, we're passionate about giving families access to beautiful bedding at prices that won't break the bank," said Ali Hassan, Director of Marketing at Latest Bedding.
  • In advance of the holiday season, Latest Bedding is expanding its online offerings to include new colors in the Pure Parima Triple Luxe Sateen Sheet line.
  • In addition to Pure Parima and Bebejan, Latest Bedding carries sheets and comforter sets by other top bedding designers, such as J Queen, Waterford, and Rose Tree.
  • For more information on the high-end bedding available at Latest Bedding, reach out to the team online.

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Retrieved on: 
Sunday, September 12, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM), and additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil in Black patients with heart failure (HF) with reduced ejection fraction (HFrEF), were presented in a Late Breaking Clinical Trials session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Denver, CO, and virtually online.

Key Points: 
  • The observed reductions in LVOT-G were dose dependent, with patients achieving greater reductions of LVOT-G with increasing doses of aficamten.
  • We look forward to investigating aficamten further in a large Phase 3 clinical trial that we expect to start by year end.
  • Cytokinetics expects to start a Phase 3 clinical trial of aficamten in patients with obstructive HCM in Q4 2021.
  • Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates.